Tirzepatide (Zepbound, Mounjaro) causes large weight loss, and a common worry is that a lot of it comes from muscle. The best data on this comes from a body-scan substudy of the SURMOUNT-1 trial. The short answer: most of the weight lost is fat, but some lean mass goes with it, and that’s worth managing on purpose.
Key takeaways
- In SURMOUNT-1, people on tirzepatide lost about 34% of their fat mass over 72 weeks, versus about 8% on placebo.
- Lean mass fell about 11% on tirzepatide versus about 3% on placebo.
- About three quarters of the weight lost was fat and one quarter was lean mass, the same ratio seen with placebo (diet and exercise counseling alone).
- “Lean mass” includes water, organs and connective tissue, not only muscle, so it overstates true muscle loss.
- Protein intake and resistance training are the main tools to protect muscle. Older adults deserve extra attention.
How tirzepatide causes fat loss
Tirzepatide activates GIP and GLP-1 receptors. The main effect is eating less: it increases fullness, reduces hunger and food “noise,” and slows stomach emptying. When you consistently eat fewer calories than you burn, your body draws on stored energy, mostly from fat tissue. GIP may also act on fat tissue directly to improve how it stores and handles fat, though that research is still developing. For the mechanism in context, see GLP-1s explained.
The body composition data
In SURMOUNT-1, a subset of 160 participants had DXA scans, which measure fat mass and lean mass separately. Results at week 72:
| Measure | Tirzepatide (pooled doses) | Placebo |
|---|---|---|
| Total fat mass | -33.9% | -8.2% |
| Lean mass | -10.9% | -2.6% |
| Share of weight lost as fat | about 75% | about 75% |
| Share of weight lost as lean mass | about 25% | about 25% |
A 2025 follow-up analysis in Diabetes, Obesity and Metabolism confirmed the ratio held across subgroups. Researchers also saw a larger drop in visceral fat, the deep belly fat most linked to diabetes and heart disease. Overall, body composition improved: people ended up with a higher percentage of lean mass than they started with.
Why some lean loss is normal
Any meaningful weight loss, whether by diet, surgery or medication, includes some lean mass. A heavier body needs more muscle and connective tissue to carry it, and some of the “lean” loss is water and organ tissue rather than skeletal muscle. In lifestyle-only weight loss studies, roughly 20 to 30% of lost weight is commonly lean mass, which is in line with what tirzepatide showed.
When muscle loss matters more
- Older adults, who already lose muscle with age, are at higher risk of weakness and falls.
- People with low muscle mass before treatment, including those with sarcopenic obesity.
- Very rapid or very large weight loss, especially with very low protein intake.
- People who are sedentary, since unused muscle is the first to go.
Muscle function matters more than the number on a scan. Signs worth discussing with your clinician include losing strength, struggling with stairs or getting up from a chair, or feeling unusually weak.
How to protect muscle on tirzepatide
Protein
A 2025 joint advisory from four major obesity and nutrition organizations named adequate protein and strength training as core priorities for people on GLP-1 medicines. Because appetite is lower, protein can fall short without planning. Practical habits:
- Eat protein first at each meal, before starches.
- Spread intake across the day rather than one large serving.
- Use easy options when appetite is low: Greek yogurt, eggs, cottage cheese, fish, tofu, lean meat or a protein shake.
- Ask a dietitian for a target suited to your weight, kidney function and activity level.
Resistance training
- Aim for strength work for all major muscle groups at least two days a week, per standard physical activity guidelines.
- Progress gradually: bodyweight moves, bands or machines all count.
- Walking and cardio help overall health but don’t protect muscle as well on their own.
Don’t under-eat
Some people eat so little on tirzepatide that they get very little protein or nutrition. Eating smaller, regular, protein-forward meals tends to work better than skipping meals.
What about muscle-sparing drugs?
Several companies are testing drugs designed to preserve muscle during GLP-1 weight loss, such as activin-pathway antibodies like bimagrumab. Early trials have shown more fat loss and less lean loss when combined with a GLP-1, but none is approved for this use. Be cautious of “muscle-sparing” peptide stacks sold online, which have no comparable evidence.
For how tirzepatide compares with newer drugs, see retatrutide vs tirzepatide. For side effects, see our GLP-1 side effects guide.
Frequently asked questions
Does tirzepatide burn fat or muscle?
Mostly fat. In SURMOUNT-1, about three quarters of weight lost on tirzepatide was fat mass and about one quarter was lean mass, the same ratio as placebo.
How much muscle do you lose on tirzepatide?
Lean mass fell about 11% over 72 weeks in SURMOUNT-1, compared with about 34% loss of fat mass. Lean mass includes water and organs, so true muscle loss is somewhat lower.
Does tirzepatide reduce belly fat?
Yes. The body composition data showed reductions in visceral (deep abdominal) fat along with total fat.
How can I keep muscle on Zepbound or Mounjaro?
Prioritize protein at every meal, do resistance training at least twice a week, and avoid extreme under-eating. A dietitian can set a protein target for you.
Is muscle loss on tirzepatide dangerous?
For most people the overall change in body composition is favorable. Older adults and people with low muscle mass should monitor strength and talk to a clinician about a plan.
Sources
- Jastreboff AM et al., Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), N Engl J Med, 2022, including DXA substudy
- Look M et al., Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study, Diabetes Obes Metab, 2025
- Mozaffarian D et al., Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory (ACLM, ASN, OMA, TOS), 2025
- U.S. Department of Health and Human Services, Physical Activity Guidelines for Americans
- Zepbound and Mounjaro U.S. prescribing information
Medical disclaimer: Pep Guide is for educational purposes only. It is not medical advice, diagnosis or treatment. Research changes over time. Talk to a licensed healthcare provider before starting, stopping or changing any medication or compound.